... TVM Capital Joins Investor Syndicate ...VIENNA Austria March 28 /- f-star an antibodyengineer...Modular Antibody Technology was originally developed by Prof. Florian... We are very pleased that our technology is now essentially free ofro...

VIENNA, Austria, March 28 /PRNewswire/ -- f-star, an antibody
engineering company developing novel antibodies and antibody fragments
based on its unique Modular Antibody Technology, announced today that it
has acquired future royalty obligations to New Century Pharmaceuticals
(NCP) via a one-off payment.

Modular Antibody Technology was originally developed by Prof. Florian
Rueker, one of f-star's founders, in collaboration with NCP, a U.S.
biopharmaceutical company. After f-star's foundation, NCP became one of the
Company's common shareholders and had rights to future royalty payments. In
the course of the transaction, f-star has now bought back these royalty
obligations and TVM Capital, a transatlantic venture capital firm based in
Munich and Boston, acquired NCP's minority stake in f-star.

"We are very pleased that our technology is now essentially free of
royalty obligations," Gottfried Himmler, CEO of f-star, commented on the
transaction. "And we are delighted to have TVM Capital, one of the leading
life science investors in Europe, joining f-star's strong international
investor syndicate."

"It is an honor to become an investor in one of the leading
next-generation antibody companies and to join this distinguished
syndicate," Axel Polack, General Partner TVM Capital, commented.

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The
Company develops improved therapeutic antibodies and antibody fragments
based on its Modular Antibody Technology, which allows the introduction of
additional binding sites into antibodies and antibody fragments by
engineering the non-CDR loops of constant or variable domains. Using
Modular Antibody Technology, antibody fragments with antibody functionality
and long half-life but much smaller size (Fcab(TM)) or full antibodies with
additional functionality (mAb squared) can be created.

f-star was founded by a team of experienced antibody engineering and
biotech executives in 2006. Seed-financed by Austrian government agencies
and Atlas Venture, the Company recently closed a Series A financing round
with Aescap Venture, Atlas Venture and Novo A/S and has raised EUR 13.0m in
total so far. In its advisory board, the Company is supported by pioneers
in the field of monoclonal antibodies. f-star has 18 employees at its
headquarters in Vienna, Austria and recently opened a second research site
in Cambridge, UK.

The TVM Capital Life Science Practice is, with EUR 900m (USD1.3bn)
under management, one of the largest investors in venture and growth deals
in biotechnology and pharmaceuticals in Europe, with a strong presence in
the U.S. and a growing presence in Asia. The Life Science team builds on
the expertise, experience, international approach and demonstrated success
in more than 100 previous investments and more than 30 IPOs from its
biotechnology and pharmaceutical portfolio of companies.
For more information, visit http://www.tvm-capital.com

(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...

(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...

(Date:11/19/2016)... DALLAS , Nov. 18, 2016 Securus ... technology solutions for public safety, investigation, corrections and monitoring, ... a smaller competitor, ICSolutions, to have an independent technology ... set, the most modern high tech/sophisticated telephone calling platform, ... tell customers that they do most of what we ...

(Date:11/15/2016)... Nov 15, 2016 Research and Markets has ... to 2021" report to their offering. ... ... Billion by 2021 from USD 6.21 Billion in 2016, growing at ... Growth of the bioinformatics market is driven by the growing demand ...